BioPharmSignal logoBioPharmSignal

Biotech News

MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance

MDxHealth (MDXH)MDxHealthEarnings

IRVINE, CA – October 15, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110–115 million.

Related news

DGXQuest Diagnostics2026-10-22 10:46 EST

Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

REPLReplimune Group2026-10-22 12:00 EST

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

ANGOAngioDynamics2026-10-08 10:02 EST

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

View all latest news

MDxHealth

Precision Urologic Diagnostics MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases. Prostate Cancer Menu The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic,...

Recent company news

MDXHMDxHealth2026-10-15 20:00 EST

MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance

MDXHMDxHealth2026-08-13 20:00 EST

Mdxhealth Reports Second Quarter 2026 Financial Results

MDXHMDxHealth2026-07-30 20:00 EST

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

MDXHMDxHealth2026-07-24 20:59 EST

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

MDXHMDxHealth2026-07-02 20:00 EST

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Stock data

Close
0.18 USD
Market cap
32.93M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States